Mice with skin tumors (12 weeks after the DMBA/TPA treatment) were treated intravenously twice (week 12 and 16) with non-replicating adenovirus encoding neutralizing soluble IL-17R (Ad-IL-17R:Fc) or GFP as a control (Ad-GFP). This evidence concerns the gene IL17RA and skin neoplasm.